Outcomes following autologous tumor tissue implantation with or without concurrent antineoplastic therapies in the treatment of sarcoids in 50 equids.
Authors: Smith Caitlin H, Stewart Holly L, Stefanovski Darko, Levine David G
Journal: Frontiers in veterinary science
Summary
# Autologous Sarcoid Tissue Implantation: Clinical Outcomes and Patient Selection Criteria Autologous tumour tissue implantation represents a relatively simple immunotherapeutic approach to sarcoid management, yet its mechanisms and predictive factors for success remain incompletely understood. Smith and colleagues conducted a retrospective analysis of 50 horses treated at the University of Pennsylvania between 2014 and 2022, evaluating complete resolution rates, the influence of concurrent antineoplastic therapies, and factors associated with recurrence and complications. Complete clinical regression without recurrence occurred in 50% of cases, with notably equivalent outcomes between horses receiving implantation alone versus those undergoing concurrent pharmacological treatment—suggesting the autoimplantation itself drives the therapeutic effect rather than adjunctive interventions. Prognosis was substantially worse for horses with previous treatment failure (77% less likely to improve), body-located lesions (48% lower odds of improvement), and higher initial tumour burdens (11% reduction in improvement odds per additional tumour); conversely, post-implantation tumour burden reduction predicted a 71% decreased recurrence risk. Serious complications were rare (only 4% developed iatrogenic tumours at implantation sites), and owner satisfaction closely tracked clinical outcomes, making this technique a justified option for carefully selected cases—particularly those with low tumour numbers, no prior failed treatments, and non-body locations—whilst highlighting the need for mechanistic research that may ultimately yield predictive biomarkers or commercial immunotherapeutic products.
Read the full abstract on PubMed
Practical Takeaways
- •Autologous tumor implantation is a technically simple option with 50% success rate; consider for cases with low tumor burden and facial/limb locations rather than body sarcoids
- •Prior treatment failures predict poor outcomes (77% less likely to improve), so this technique may not be suitable for refractory cases
- •Combined antineoplastic therapy does not improve results over implantation alone, so can simplify treatment protocols and reduce client costs
Key Findings
- •Complete resolution without recurrence achieved in 50% of cases treated with autologous tumor tissue implantation
- •No significant difference in outcomes between autoimplantation alone versus autoimplantation combined with concurrent antineoplastic therapies
- •Body-localized sarcoids had 48% lower odds of clinical improvement, and each additional tumor decreased improvement odds by 11%
- •Severe complications were uncommon (4% developed tumors at implantation site); client satisfaction correlated with recurrence rates